Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared a post by ECOG-ACRIN Cancer Research Group on X, adding:
”So excited to see our hard work along with my friend Monika Joshimd (Study Chair) come to fruition opening this important phase 3 trial asking ICI rechallenge question in advanced urothelial Ca! We appreciate if you could open it at your sites! Fred Hutch Cancer Center thanks ECOG-ACRIN Cancer Research Group dream team.”
Quoting ECOG-ACRIN Cancer Research Group‘s post:
”Phase 3 Clinical Trial EA8231 is now enrolling!
This study is exploring a new treatment approach for pts with treatment-refractory locally-advanced or metastatic Urothelial Cancer.
More posts featuring Petros Grivas on OncoDaily.